{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:07:37Z","timestamp":1784977657693,"version":"3.55.0"},"reference-count":131,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>This article concisely evaluates current targeted therapies that have received regulatory approval for chronic lymphocytic leukemia (CLL). Mechanisms of molecular pathogenesis and their therapeutic implications, current and novel targeted therapies, and supportive care are discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>CLL is a common lymphoproliferative neoplasm of mature but immunologically incompetent B cells in older adults. Over the past 2 decades, robust research has shown that CLL pathogenesis is a multistep process that includes, but is not limited to, (1) clonal selection, expansion, and transformation; (2) aberrant B cell signaling pathways; (3) sequence heterogeneity in the gene encoding the immunoglobulin heavy chain variable region (IGHV); (4) impaired apoptosis; and (5) interactions between CLL cells and their microenvironment. The development of oral targeted therapies against some of these molecular abnormalities has led to improved survival outcomes over traditional chemoimmunotherapy. Current oral targeted therapies that have received regulatory approval include continuous therapy with Bruton\u2019s tyrosine kinase inhibitors (BTKis) and fixed-duration therapy with the B cell leukemia\/lymphoma-2 inhibitor (BCL-2i) venetoclax. These agents may be used either alone or in combination in the treatment-naive setting, as well as in relapsed or refractory disease. This review contributes to understanding of the molecular pathogenesis of CLL with therapeutic implications. It summarizes key advances in oral targeted therapies and emerging innovative targeted therapies (eg, novel BTKis, BTK degraders, and novel BCL-2is) and highlights supportive care in optimizing treatment-related adverse effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment options for CLL continue to evolve. Current treatment selection is based on clinical and patient-specific considerations. Emerging novel therapies to overcome treatment resistance and strategies to optimize supportive care generate opportunities for pharmacists to advance practice and improve patient safety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf058","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:35:22Z","timestamp":1741757722000},"page":"868-885","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care"],"prefix":"10.1093","volume":"82","author":[{"given":"Clement","family":"Chung","sequence":"first","affiliation":[{"name":"Houston Methodist West Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2025081213365507500_CIT0001","author":"National Cancer Institute"},{"issue":"1","key":"2025081213365507500_CIT0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"2025081213365507500_CIT0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2017.1.329","article-title":"The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment","volume":"2017","author":"Gaidano","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"2025081213365507500_CIT0004","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025081213365507500_CIT0005","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bjhh.2016.07.004","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia","volume":"38","author":"Arrais Rodrigues","year":"2016","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"7","key":"2025081213365507500_CIT0006","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u20142024 update","volume":"38","author":"Malcikova","year":"2024","journal-title":"Leukemia"},{"key":"2025081213365507500_CIT0007","author":"National Comprehensive Cancer Network","year":"2024"},{"issue":"2","key":"2025081213365507500_CIT0008","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ccr.2011.06.029","article-title":"Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia","volume":"20","author":"Kikushige","year":"2011","journal-title":"Cancer Cell"},{"issue":"3","key":"2025081213365507500_CIT0009","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2025081213365507500_CIT0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/miR-15a\/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia","volume":"17","author":"Klein","year":"2010","journal-title":"Cancer Cell"},{"issue":"4","key":"2025081213365507500_CIT0011","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2025081213365507500_CIT0012","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2025081213365507500_CIT0013","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3960\/jslrt.20036","article-title":"Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies","volume":"60","author":"Kikushige","year":"2020","journal-title":"J Clin Exp Hematop"},{"issue":"8","key":"2025081213365507500_CIT0014","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1038\/bcj.2017.77","article-title":"Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis","volume":"7","author":"Kostopoulos","year":"2017","journal-title":"Blood Cancer J"},{"issue":"24","key":"2025081213365507500_CIT0015","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2013-10-534073","article-title":"Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells","volume":"123","author":"Rozovski","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2025081213365507500_CIT0016","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2025081213365507500_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2018.02.001","article-title":"Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact","volume":"51","author":"Mansouri","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2025081213365507500_CIT0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000533610","article-title":"Chronic lymphocytic leukemia: disease biology","volume":"147","author":"Koehrer","year":"2024","journal-title":"Acta Haematol"},{"issue":"1","key":"2025081213365507500_CIT0019","first-page":"55","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies","volume":"14","author":"Koehrer","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"6-7","key":"2025081213365507500_CIT0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol Immunol"},{"issue":"11","key":"2025081213365507500_CIT0021","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2853","article-title":"The tipping points in the initiation of B cell signalling: how small changes make big differences","volume":"10","author":"Pierce","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2025081213365507500_CIT0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"6","key":"2025081213365507500_CIT0023","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1073\/pnas.050583597","article-title":"Posttranscriptional regulation of Bruton\u2019s tyrosine kinase expression in antigen receptor-stimulated splenic B cells","volume":"97","author":"Nisitani","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"28","key":"2025081213365507500_CIT0024","doi-asserted-by":"crossref","first-page":"23769","DOI":"10.1074\/jbc.M112.372425","article-title":"Tyrosine kinase Btk is required for NK cell activation","volume":"287","author":"Bao","year":"2012","journal-title":"J Biol Chem"},{"issue":"12","key":"2025081213365507500_CIT0025","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1084\/jem.20120833","article-title":"Cellular origin and pathophysiology of chronic lymphocytic leukemia","volume":"209","author":"Seifert","year":"2012","journal-title":"J Exp Med"},{"issue":"6","key":"2025081213365507500_CIT0026","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0167-5699(94)90009-4","article-title":"The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire","volume":"15","author":"Schroeder","year":"1994","journal-title":"Immunol Today"},{"issue":"6","key":"2025081213365507500_CIT0027","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2010-07-155663","article-title":"Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities","volume":"117","author":"Chiorazzi","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2025081213365507500_CIT0028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.seminhematol.2024.04.002","article-title":"Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia","volume":"61","author":"Patton","year":"2024","journal-title":"Semin Hematol"},{"issue":"7415","key":"2025081213365507500_CIT0029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Duhren-von Minden","year":"2012","journal-title":"Nature"},{"issue":"11","key":"2025081213365507500_CIT0030","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"Klein","year":"2001","journal-title":"J Exp Med"},{"issue":"11","key":"2025081213365507500_CIT0031","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J Exp Med"},{"issue":"19","key":"2025081213365507500_CIT0032","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2025081213365507500_CIT0033","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41375-018-0303-x","article-title":"The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia","volume":"33","author":"Ten Hacken","year":"2019","journal-title":"Leukemia"},{"key":"2025081213365507500_CIT0034","doi-asserted-by":"crossref","first-page":"15746","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2025081213365507500_CIT0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.15018","article-title":"The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab","volume":"180","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"15","key":"2025081213365507500_CIT0036","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/febs.13683","article-title":"Bcl-2 proteins in development, health, and disease of the hematopoietic system","volume":"283","author":"Kollek","year":"2016","journal-title":"FEBS J"},{"issue":"5","key":"2025081213365507500_CIT0037","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.coi.2007.06.002","article-title":"Life and death during hematopoietic differentiation","volume":"19","author":"Opferman","year":"2007","journal-title":"Curr Opin Immunol"},{"issue":"39","key":"2025081213365507500_CIT0038","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2025081213365507500_CIT0039","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2025081213365507500_CIT0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2146\/ajhp170607","article-title":"Restoring the switch for cancer cell death: targeting the apoptosis signaling pathway","volume":"75","author":"Chung","year":"2018","journal-title":"Am J Health-Syst Pharm"},{"issue":"15","key":"2025081213365507500_CIT0041","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.3390\/ijms241512471","article-title":"Role of microRNAs in chronic lymphocytic leukemia","volume":"24","author":"Autore","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"16","key":"2025081213365507500_CIT0042","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2025081213365507500_CIT0043","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1080\/10428194.2022.2064995","article-title":"The role of BTK inhibitors on the tumor microenvironment in CLL","volume":"63","author":"McCay","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025081213365507500_CIT0044","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","article-title":"LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia","volume":"30","author":"Nguyen","year":"2016","journal-title":"Cancer Cell"},{"issue":"5","key":"2025081213365507500_CIT0045","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2004-12-4918","article-title":"Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells","volume":"106","author":"Burger","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2025081213365507500_CIT0046","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2006-06-027755","article-title":"BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-\u03baB pathway","volume":"109","author":"Endo","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2025081213365507500_CIT0047","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2025081213365507500_CIT0048","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Invest"},{"key":"2025081213365507500_CIT0049","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hon.3166_OT10","article-title":"Epcoritamab monotherapy and combinations in relapsed or refractory chronic lymphocytic leukemia or Richter\u2019s syndrome: new escalation and expansion cohorts in EPCORE CLL-1","volume":"41","author":"Eichhorst","year":"2023","journal-title":"Hematol Oncol"},{"key":"2025081213365507500_CIT0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2013.1.158","article-title":"Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers","volume":"2013","author":"Shanafelt","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2025081213365507500_CIT0051","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","article-title":"A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients","volume":"56","author":"Salvi","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"17","key":"2025081213365507500_CIT0052","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.3390\/cancers15174391","article-title":"The five \u201cWs\u201d of frailty assessment and chronic lymphocytic leukemia: who, what, where, why, and when","volume":"15","author":"Gonz\u00e1lez-Gasc\u00f3n-y-Mar\u00edn","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"2025081213365507500_CIT0053","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17474086.2024.2366534","article-title":"Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints","volume":"17","author":"Molica","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2025081213365507500_CIT0054","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025081213365507500_CIT0055","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/curroncol28010037","article-title":"Impact of oral targeted therapy on the economic burden of chronic lymphocytic leukemia in Canada","volume":"28","author":"Lachaine","year":"2021","journal-title":"Curr Oncol"},{"issue":"5","key":"2025081213365507500_CIT0056","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.3390\/curroncol30050339","article-title":"Impact of fixed-duration oral targeted therapies on the economic burden of chronic lymphocytic leukemia in Canada","volume":"30","author":"Lachaine","year":"2023","journal-title":"Curr Oncol"},{"issue":"5","key":"2025081213365507500_CIT0057","first-page":"430","article-title":"Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia","volume":"30","author":"Lee","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2025081213365507500_CIT0058","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/HS9.0000000000000336","article-title":"Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG)","volume":"4","author":"Kutsch","year":"2020","journal-title":"Hemasphere"},{"issue":"10","key":"2025081213365507500_CIT0059","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.clml.2023.07.011","article-title":"SOHO State of the Art Updates and Next Questions: Updates on BTK inhibitors for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Easaw","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025081213365507500_CIT0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/asheducation-2018.1.248","article-title":"Relapsed CLL: sequencing, combinations, and novel agents","volume":"1","author":"Brown","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2025081213365507500_CIT0061","doi-asserted-by":"crossref","first-page":"e2019024","DOI":"10.4084\/mjhid.2019.024","article-title":"Relapsed\/refractory chronic lymphocytic leukemia: chemoimmunotherapy, treatment until progression with mechanism-driven agents or finite-duration therapy","volume":"11","author":"Cuneo","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"2025081213365507500_CIT0062","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"31","key":"2025081213365507500_CIT0063","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025081213365507500_CIT0064","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"31","key":"2025081213365507500_CIT0065","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025081213365507500_CIT0066","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"2025081213365507500_CIT0067","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/bloodadvances.2020002593","article-title":"Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists","volume":"4","author":"Koenig","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2025081213365507500_CIT0068","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"13","key":"2025081213365507500_CIT0069","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025081213365507500_CIT0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2025081213365507500_CIT0071","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"2025081213365507500_CIT0072","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2025081213365507500_CIT0073","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081213365507500_CIT0074","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2025081213365507500_CIT0075","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long term follow-up of the RESONATE phase 3 trial of ibrutinib versus ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081213365507500_CIT0076","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025081213365507500_CIT0077","doi-asserted-by":"crossref","first-page":"102089","DOI":"10.1016\/j.isci.2021.102089","article-title":"Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways","volume":"24","author":"Edelmann","year":"2021","journal-title":"iScience"},{"issue":"suppl 1","key":"2025081213365507500_CIT0078","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies","volume":"132","author":"Kapten","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2025081213365507500_CIT0079","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"2025081213365507500_CIT0080","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025081213365507500_CIT0081","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1007\/s12325-022-02238-7","article-title":"Zanubrutinib monotherapy for naive and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: a pooled analysis of three studies","volume":"39","author":"Xu","year":"2022","journal-title":"Adv Ther"},{"issue":"11","key":"2025081213365507500_CIT0082","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2025081213365507500_CIT0083","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic\u00a0leukemia: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"11","key":"2025081213365507500_CIT0084","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","article-title":"An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL","volume":"8","author":"Kittai","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"2025081213365507500_CIT0085","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025081213365507500_CIT0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2023.10.006","article-title":"SOHO State of the Art Updates and Next Questions: Understanding and overcoming venetoclax resistance in hematologic malignancies","volume":"24","author":"Forsberg","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2025081213365507500_CIT0087","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2025081213365507500_CIT0088","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2025081213365507500_CIT0089","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2025081213365507500_CIT0090","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3390\/cancers15092596","article-title":"The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: future perspectives","volume":"15","author":"Eyre","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"2025081213365507500_CIT0091","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025081213365507500_CIT0092","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.clml.2023.01.009","article-title":"SOHO State of the Art Updates and Next Questions: New targetable pathways in chronic lymphocytic leukemia","volume":"23","author":"Fakhri","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025081213365507500_CIT0093","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025081213365507500_CIT0094","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2019.241539","article-title":"Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia","volume":"106","author":"Eyre","year":"2021","journal-title":"Haematologica"},{"issue":"34","key":"2025081213365507500_CIT0095","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025081213365507500_CIT0096","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025081213365507500_CIT0097","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2025081213365507500_CIT0098","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2025081213365507500_CIT0099","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cWhat\u2019s past is prologue\u201d (Shakespeare)","volume":"28","author":"Mato","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025081213365507500_CIT0100","author":"Secura Bio"},{"issue":"15","key":"2025081213365507500_CIT0101","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"2025081213365507500_CIT0102","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2018-06-860593","article-title":"A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081213365507500_CIT0103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2023-181774","article-title":"Impact of ibrutinib dose reduction on duration of therapy in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood"},{"issue":"35","key":"2025081213365507500_CIT0104","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"2025081213365507500_CIT0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","article-title":"Ibrutinib dose modifications in the management of CLL","volume":"13","author":"Hardy-Abeloos","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2025081213365507500_CIT0106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14740\/jh676","article-title":"Outcomes of reduced frequency dosing of ibrutinib in chronic lymphocytic leukemia patients following complete or partial remission: a pilot study","volume":"9","author":"Alexander","year":"2020","journal-title":"J Hematol"},{"issue":"2","key":"2025081213365507500_CIT0107","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2025081213365507500_CIT0108","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cpdd.1153","article-title":"Bioequivalence and relative bioavailability studies to assess a new acalabrutinib formulation that enables coadministration with proton-pump inhibitors","volume":"11","author":"Sharma","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025081213365507500_CIT0109","author":"Calquence","year":"2024"},{"key":"2025081213365507500_CIT0110","author":"Brukinsa","year":"2024"},{"key":"2025081213365507500_CIT0111","author":"Imbruvica","year":"2024"},{"key":"2025081213365507500_CIT0112","author":"Venclexta","year":"2022"},{"key":"2025081213365507500_CIT0113","author":"Jaypirca","year":"2024"},{"issue":"1","key":"2025081213365507500_CIT0114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov"},{"issue":"suppl","key":"2025081213365507500_CIT0115","doi-asserted-by":"crossref","first-page":"e7809236","DOI":"10.1097\/01.HS9.0000969416.78092.36","article-title":"Updated analysis of BELLWAVE-001: a phase 1\/2 open-label dose-expansion study of the efficacy and safety of nemtabrutinib for the treatment of B-cell malignancies","volume":"7","author":"Woyach","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2025081213365507500_CIT0116","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2022-170985","article-title":"Novel BTK mutations conferring resistance to the second-generation, irreversible BTK inhibitor orelabrutinib (ICP-022)","volume":"140","author":"Zhu","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081213365507500_CIT0117","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood-2022-163268","article-title":"Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders","volume":"140","author":"Montoya","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025081213365507500_CIT0118","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"14","key":"2025081213365507500_CIT0119","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2025081213365507500_CIT0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2022-168003","article-title":"Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025081213365507500_CIT0121","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025081213365507500_CIT0122","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025081213365507500_CIT0123","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081213365507500_CIT0124","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2025081213365507500_CIT0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"2025081213365507500_CIT0126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2025081213365507500_CIT0127","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"suppl","key":"2025081213365507500_CIT0128","doi-asserted-by":"crossref","first-page":"e98838e7","DOI":"10.1097\/01.HS9.0000969220.98838.e7","article-title":"P579: safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD5991 in relapsed\/refractory hematologic malignancies: a phase 1 first-in-human study","volume":"7","author":"Desai","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2025081213365507500_CIT0129","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2023-183071","article-title":"Updated efficacy and safety results of lisaftoclax (APG-2575) in patients (pts) with heavily pretreated chronic lymphocytic leukemia (CLL): pooled analyses of two clinical trials","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025081213365507500_CIT0130","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8 suppl","key":"2025081213365507500_CIT0131","doi-asserted-by":"crossref","first-page":"CT021","DOI":"10.1158\/1538-7445.AM2023-CT021","article-title":"Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib","volume":"83","author":"Rogers","year":"2023","journal-title":"Cancer Res"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf058\/62384308\/zxaf058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/16\/868\/62384308\/zxaf058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/16\/868\/62384308\/zxaf058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:37:21Z","timestamp":1755020241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/16\/868\/8071422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":131,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,3,11]]},"published-print":{"date-parts":[[2025,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf058","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,15]]},"published":{"date-parts":[[2025,3,11]]}}}